Literature DB >> 24958443

Sexual disorders in men with multiple sclerosis: evaluation and management.

J G Prévinaire1, G Lecourt2, J M Soler3, P Denys4.   

Abstract

Sexual dysfunction (SD) is a common feature of men with multiple sclerosis. SD is often unrecognized as patients and physicians are reluctant to discuss these problems. Rates of symptoms range from 50% to 90% and include erectile dysfunction, ejaculatory dysfunction, orgasmic dysfunction and reduced libido. SD can arise at any stage of the disease, even without severe disability. While erectile dysfunction is thought to be related to impairment of the pathways in the spinal cord, fatigue, spasticity, bladder and bowel dysfunction, and pain, contribute to SD. Psychosocial and cultural issues also need evaluating, and include depression, performance anxiety, lowered self-esteem. A comprehensive assessment of all theses aspects must be taken into account. Erectile dysfunction can be treated with phosphodiesterase inhibitors and intracavernous injections, with good efficacy. Ejaculatory dysfunction is managed through penile vibratory stimulation and midodrine. Concerning fertility issues, the effects of or immunomodulating drugs on semen quality are largely unknown, whereas many immunosuppressive therapies have a negative effect on semen quality that may be definitive. Advanced methods of assisted reproduction may sometimes be the only option for conception. Physicians' awareness of this problem may help to bring about appropriate treatments, and improve the quality of life for these patients.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Dysfonction éjaculatoire; Dysfonction érectile; Ejaculation dysfunction; Erectile dysfunction; Inhibiteurs de la phosphodiéstrase; Injections intracaverneuses; Intracavernous injections; Midodrine; Multiple sclerosis; Penile vibratory stimulation; Phosphodiesterase inhibitors; Sclérose en plaques; Stimulation vibratoire pénienne

Mesh:

Year:  2014        PMID: 24958443     DOI: 10.1016/j.rehab.2014.05.002

Source DB:  PubMed          Journal:  Ann Phys Rehabil Med        ISSN: 1877-0657


  7 in total

Review 1.  Fertility treatment in spinal cord injury and other neurologic disease.

Authors:  Vera Trofimenko; James M Hotaling
Journal:  Transl Androl Urol       Date:  2016-02

2.  Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis.

Authors:  Pawel Bartnik; Aleksandra Wielgoś; Joanna Kacperczyk; Katarzyna Pisarz; Iwona Szymusik; Aleksandra Podlecka-Piętowska; Beata Zakrzewska-Pniewska; Miroslaw Wielgoś
Journal:  Brain Behav       Date:  2017-04-14       Impact factor: 2.708

3.  Lower urinary tract symptoms and sexual dysfunction in men with multiple sclerosis.

Authors:  André Luiz Farinhas Tomé; Eduardo P Miranda; José de Bessa Júnior; Carlos Alberto Bezerra; Antônio Carlos Lima Pompeo; Sidney Glina; Cristiano Mendes Gomes
Journal:  Clinics (Sao Paulo)       Date:  2019-03-14       Impact factor: 2.365

4.  Prevalence of Sexual Dysfunction and Related Risk Factors in Men with Multiple Sclerosis in Iran: A Multicenter Study.

Authors:  Seyed Massood Nabavi; Maryam Dastoorpoor; Nastaran Majdinasab; Narges Khodadadi; Narges Khanjani; Zohreh Sekhavatpour; Maryam Zamanian; Sasan Kazemian; Amir Ebrahim Eftekhari; Fereshteh Ashtari; Roya Abolfazli; Mahdi Jalili; Gholamhossein Ghaedi; Hamid Reza Ghalianchi
Journal:  Neurol Ther       Date:  2021-05-18

Review 5.  Symptomatic management in multiple sclerosis.

Authors:  Pushkar Shah
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

6.  Kinetics of T cell response in the testes and CNS during experimental autoimmune encephalomyelitis: Simultaneous blood-brain and -testis barrier permeability?

Authors:  Nafiseh Pakravan; Ameneh Ghaffarinia; Shahram Parvaneh; Cyrus Jalili; Farhad Riazi-Rad
Journal:  Iran J Basic Med Sci       Date:  2019-07       Impact factor: 2.699

7.  Sexual dysfunction in women with multiple sclerosis: prevalence and impact on quality of life.

Authors:  Fatemeh Nazari; Vahid Shaygannejad; Mehrdad Mohammadi Sichani; Marjan Mansourian; Valiollah Hajhashemi
Journal:  BMC Urol       Date:  2020-02-21       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.